Evidence for acute stimulation of fibrinogen production by glucagon in humans

被引:20
作者
Tessari, P [1 ]
Iori, E [1 ]
Vettore, M [1 ]
Zanetti, M [1 ]
Kiwanuka, E [1 ]
Davanzo, G [1 ]
Barazzoni, R [1 ]
机构
[1] UNIV PADUA,DEPT METAB DIS,I-35100 PADUA,ITALY
关键词
D O I
10.2337/diabetes.46.8.1368
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fibrinogen, an acute-phase protein, and glucagon, a stress hormone, are often elevated in many conditions of physical and metabolic stress, including uncontrolled diabetes. However, the possible mechanisms for this association are poorly known. We have studied the acute effects of selective hyperglucagonemia (raised from similar to 200 to similar to 350 pg/ml for 3 h) on fibrinogen fractional secretion rate (FSR) in eight normal subjects during infusion of somatostatin and replacement doses of insulin, glucagon, and growth hormone. Fibrinogen FSR was evaluated by precursor-product relationships using either Phe (n = 8) or Leu (n = 2) tracers. Hyperglucagonemia did not change either plasma Phe or Tyr specific activity. After hyperglucagonemia, fibrinogen FSR increased by similar to 65% (from 12.9 +/- 3.6 to 21.5 +/- 6.1% per day, P < 0.025) using plasma Phe specific activity as the precursor pool. FSR increased by similar to 80% (from 16.6 +/- 4.8 to 29.4 +/- 8.8% per day, P < 0.025) if plasma Phe specific activity was corrected for the ketoisocaproate/Leu enrichment (or specific activity) ratio to obtain an approximate estimate of intrahepatic Phe specific activity. FSR increased by similar to 60% when using plasma Tyr specific activity as precursor pool (n = 8) (P < 0.05), as well as when using the Leu tracer precursor-product relationship (n = 2). In conclusion, selective hyperglucagonemia for similar to 3 h acutely stimulated fibrinogen FSR using a Phe tracer method. Thus, glucagon may be involved in the increase of fibrinogen concentration and FSR observed under stressed or pathologic conditions.
引用
收藏
页码:1368 / 1371
页数:4
相关论文
共 37 条
[11]   FIBRINOGEN [J].
ERNST, E .
BRITISH MEDICAL JOURNAL, 1991, 303 (6803) :596-597
[12]   HYPERFIBRINOGENEMIA - AN IMPORTANT RISK FACTOR FOR VASCULAR COMPLICATIONS IN DIABETES [J].
GANDA, OP ;
ARKIN, CF .
DIABETES CARE, 1992, 15 (10) :1245-1250
[13]  
GORDON AH, 1976, PLASMA PROTEIN TURNO, P381
[14]   DETERMINATION OF LEUCINE AND ALPHA-KETOISOCAPROIC ACID CONCENTRATIONS AND SPECIFIC ACTIVITY IN PLASMA AND LEUCINE SPECIFIC ACTIVITIES IN PROTEINS USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
HORBER, FF ;
KAHL, J ;
LECAVALIER, L ;
KROM, B ;
HAYMOND, MW .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 495 :81-94
[15]   FIBRINOGEN AND RISK OF CARDIOVASCULAR-DISEASE - THE FRAMINGHAM-STUDY [J].
KANNEL, WB ;
WOLF, PA ;
CASTELLI, WP ;
DAGOSTINO, RB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 258 (09) :1183-1186
[16]   DIABETES AND CARDIOVASCULAR-DISEASE - FRAMINGHAM-STUDY [J].
KANNEL, WB ;
MCGEE, DL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1979, 241 (19) :2035-2038
[17]  
LICKLEY HLA, 1983, GLUCAGON, V2, P297
[18]  
McMillan DE, 1992, INT TXB DIAB MELLITU, P1447
[19]  
MILLER LL, 1975, BIOCHEM ACTION HORM, P159
[20]  
MILLWARD DJ, 1991, P NUTR SOC, V50, P195